Zirconium-89 DFO MSTP 2109A

Drug Profile

Zirconium-89 DFO MSTP 2109A

Alternative Names: 89Zr-DFO-MSTP2109A; Zirconium89 DFO MSTP2109A

Latest Information Update: 18 Feb 2016

Price : $50

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Genentech; Memorial Sloan-Kettering Cancer Center
  • Class Immunoconjugates; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Prostate cancer

Most Recent Events

  • 18 Feb 2016 Phase-I/II development is ongoing in USA
  • 18 Aug 2015 Memorial Sloan Kettering Cancer Center and Genentech complete enrolment in a phase I/II trial for Prostate cancer (Diagnosis) in USA (NCT01774071)
  • 18 Jan 2013 Phase-I/II clinical trials in Prostate cancer (Diagnosis) in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top